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Introduction
Class II major histocompatibility complex (MHC) mole-
cules expose specific peptides at the cell surface of anti-
gen-presenting cells to CD4-expressing T cells (Unanue,
1984). These peptides are generated by proteolysis of larger
protein antigens taken up from the extracellular medium via
the endocytic pathway. Subsequently the peptides bind class
II molecules and the complex is routed to the cell surface.
While it is clear that both the proteolytic processing events
and the binding of specific peptide fragments to class II
molecules occur somewhere in the endocytic pathway, the
precise site(s) where these events occur remains to be estab-
lished (Brodsky, 1992). 
MHC class II molecules consist of polymorphic a and b
chains, which associate with invariant chain (Ii) directly
after insertion into the ER membrane (Kvist et al., 1982;
Jones et al., 1978). Ii is a type II transmembrane protein
exposing 30 N-terminal residues on the cytoplasmic side
and a large C-terminal domain of ~ 160 amino acids on the
exoplasmic side of the membrane (Claesson et al., 1983).
Recent findings suggest that Ii may play an important role
in the regulation of peptide binding to MHC class II mol-
ecules (Koch et al., 1989; Long et al., 1989). Since MHC
class II molecules with assembled Ii were found to be
unable to bind peptides, it was concluded that Ii prevents
peptide binding in the early compartments of the biosyn-
thetic pathway by occupying the peptide binding site on
MHC class II molecules. The second proposed function of
Ii is to sort MHC class II molecules into endocytic com-
partments. This is supported by the finding that the N-ter-
mi al tail of Ii contains an endosomal sorting signal (Bakke
and Dobberstein, 1990; Lotteau et al., 1990).
In a recent immunocytochemical study of Mel Juso cells,
oth MHC class II molecules and Ii could be detected in
three distinct endocytic compartments. These were the early
endosomes, the multivesicular body-like endosome carrier
vesicle (ECV) and the cation-independent mannose 6-phos-
phate (MPR)-enriched prelysosomal compartment (PLC)
(Pi t rs et al., 1991). In B-lymphoblastoid cells, class II
molecules are found mainly in structures classified as lyso-
somes (Peters et al., 1991).
During intracellular transport Ii is proteolytically
processed and dissociates from the complex with class II
molecules at an intracellular site. Processing occurs in dis-
tinct st ps from the C terminus of the molecule (Pieters et
al., 1991). In B-lymphoblastoid cells processing intermedi-
ates of Ii can only be seen after inhibition of proteolysis
with leupeptin (Kvist et al., 1982; Blum and Cresswell,
1988). In the human melanoma cell line, Mel Juso, this pro-
teolysis results in the sequential formation of the process-
ing intermediates P22, P18 and P12, each lacking increas-
ingly larger portions from the C-terminal side (Pieters et
al., 1991).
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Invariant chain (Ii) associated with MHC class II mol-
ecule is processed proteolytically via several distinct
intermediates during its intracellular transport through
endosomal compartments. Leupeptin added to the cul-
ture medium blocks processing of Ii, prevents its disso-
ciation from the class II molecules and leads to an intra-
cellular accumulation of a 22 kDa intermediate form of
Ii. We show here that leupeptin has a very general effect
on protein transport in the endocytic pathway. When
added to Mel Juso cells leupeptin reduces the transport
of endocytosed material from multivesicular body-like,
endosome carrier vesicles (ECV) to the prelysosomal
compartment (late endosome) and leads to a concomi-
tant increase in the number of ECV. Our results argue
that one effect of leupeptin, related to antigen process-
ing and presentation, is to block transport of antigen
and/or MHC class II molecules to prelysosomal com-
partments.
Key words: leupeptin, invariant chain (Ii), endosome carrier
vesicle (ECV), endocytosis.
Summary
A block in degradation of MHC class II-associated invariant chain
correlates with a reduction in transport from endosome carrier vesicles to
the prelysosome compartment
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Processing of Ii can be inhibited by protease inhibitors,
such as leupeptin, added to the culture medium, or by agents
which increase the pH of endosomes, such as chloroquine
(Blum and Cresswell, 1988). Leupeptin mainly inhibits
thiol proteases such as cathepsin B, plasmin and papain,
but has little or no activity in inhibiting the thiol protease
cathepsin A and the acid protease cathepsin D (Aoyagi and
Umezawa, 1975). In Mel Juso cells, leupeptin treatment
over 4 h leads to an accumulation of P22, the first degra-
dation product of Ii. In this paper we describe the effect of
leupeptin on the localization of the MHC class II-associ-
ated Ii in Mel Juso cells. Our data show that leupeptin sig-
nificantly retards the transport of a fluid-phase marker
horseradish peroxidase (HRP) from the ECV to the PLC.
A consequence of this block is that the total number of
ECV per cell increases about two-fold.
Materials and methods
Cell culture
The Mel Juso cell line is derived from a human malignant
melanoma (Johnson et al., 1981) and was obtained from Dr. G.
Riethmüller, University of Munich. The cells were cultured in
RPMI 1640 medium supplemented with 10% foetal calf serum
(RPMI-FCS).
Antibodies
The hybridoma cell line L-243 secreting anti-HLA-DR antibodies
(Lampson and Levy, 1980) was obtained from the American Type
Culture Collection. Ascites fluid was obtained by culturing the
cells intraperitonally in Balb/c mice. VIC Y1 (Quaranta et al.,
1984) is a mouse monoclonal antibody that recognizes a cytoso-
lic epitope within the 30 N-terminal amino acids of Ii. LN2
(Biotest AG, FRG) is a mouse monoclonal antibody specific for
an epitope in the outer C-terminal portion of Ii (within amino acids
157-216 of Ii; Wraight et al., 1990). The polyclonal rabbit anti-
body, anti-IiN, recognizes the N-terminal cytoplasmic segment of
Ii. The antiserum was raised against a fusion protein of b -galac-
tosidase and the N-terminal 73 amino acids (Ii1-73) of  as
described previously (Lipp and Dobberstein, 1986).
Rabbit polyclonal antisera specific for the (cation-independent)
mannose 6-phosphate receptor (MPR) and for horseradish perox-
idase (HRP) were gifts from Drs. B. Hoflack and J. Gruenberg,
respectively.
Immunofluorescence studies
Mel Juso cells were grown on coverslips (1 cm ´ 1 cm) and for
leupeptin experiments 150 µg/ml leupeptin (Sigma) was added to
the medium. The immunofluorescence labelling was carried out
as previously described by Bakke and Dobberstein (1990). Briefly,
the cells were fixed in 3% paraformaldehyde (PFA) and perme-
abilized with 0.1% Triton X-100. They were labelled with the
appropriate antibody (VIC Y1 or LN2) on ice and Ii was visual-
ized by using a FITC-conjugated second antibody. After labelling,
the cells were mounted in Moviol and examined using a Leitz
Orthoplan fluorescence photo-microscope equipped with a ´ 63
objective and filters for FITC.
Metabolic labelling and pulse-chase protocol
Mel Juso cells, cultured in 35 mm dishes, were incubated in pre-
warmed, methionine-free medium. After 30 min this medium was
replaced by methionine-free medium containing 0.08 mCi
[35S]m thionine. After 30 min pulse labelling the cells were
washed twice and further incubated in prewarmed chase medium
(RPMI-FCS with 4 mM methionine). After the chase times indi-
cated in the figure legend, the cells were placed on ice and washed
2´ with ice-cold PBS. The cells were lysed for 10 min on ice with
ice-cold lysis buffer (1% Triton X-100, 50 mM Tris-HCl, pH 7.5,
150 mM NaCl, 0.1 mM PMSF). The cell lysates were centrifuged
at 10,000 g for 2 min at 4°C to remove cell debris and antigens
immunoprecipitated from the supernatants.
Leupeptin treatment
Cells were metabolically labelled as described above using
medium containing 150 µg/ml leupeptin for 4 h. The medium was
subsequently replaced by methionine-free medium with the same
concentration of leupeptin. All of the following steps were con-
ducted as in the usual protocol, except that all media additionally
contained 150 µg/ml leupeptin.
Immunoprecipitation and electrophoresis
A 40 µl sample of Protein A-Sepharose (1:1 slurry) equilibrated
in buffer A (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM
EDTA, 0.2% NP-40) was added to the cell lysates and adsorbed
for 30 min at 4°C. The beads were removed by centrifugation and
1 µl of the anti-MHC class II antibody L-243 was added to the
supernatant and incubated for 2 h at 4°C. A further 20 µl Protein
A-Sepharose was added, followed by a 1 h incubation. The beads
were washed twice in buffer A, twice in buffer A containing 500
mM NaCl, and twice in 10 mM Tris-HCl, pH 7.5. The antigens
were eluted from the beads by the addition of sample buffer, dena-
tured and analyzed by electrophoresis on a 10% to 15% gradient
polyacrylamide gel and subjected to fluorography and autoradi-
o raphy.
Electron microscopy
Epon sections
I  order to identify all the compartments of the endocytic path-
way, cells were incubated for 10 h at 37°C in prewarmed RPMI
(5% FCS; ± 150 µg/ml leupeptin) containing 5 mg/ml HRP
(Sigma, type VI). After 10 h endocytosis was stopped by removing
the medium, the dishes were then placed on ice and washed twice
in ice-cold PBS. Preparation of cells for plastic embedding using
Epon 812 was performed as described previously (Griffiths et al.,
1984a), except that after osmium tetroxide treatment the cells were
treated with 1.5% uranyl acetate in 50 mM Tris-maleate buffer,
pH 5, for 30 min. The visualization of HRP with diamino-benzi-
dine (DAB; Sigma Chemical Co.) was done as described by Grif-
fi ths et al. (1989).
Cryomicrotomy and immunocytochemistry
Dishes with a nearly confluent monolayer were placed on ice and
cells were removed by treatment with proteinase K (50 µg/ml in
PBS) and fixed in 8% formaldehyde in 250 mM Hepes-buffer (pH
7.4). The preparation of cryo-sections as well as single and double
labelling with antibodies and Protein A-gold were performed as
described (Griffiths et al., 1984b, 1988).
Markers for endocytosis
For identification of the various compartments belonging to the
endocytic pathway, cells were incubated for various times in
medium containing BSA-gold complexes of different sizes. To
identify early and late endosomes, cells were allowed to internal-
ize a BSA-5 nm gold complex for 30 min. To identify late endo-
cytic structures, a BSA-16 nm gold complex was internalized for
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4 h, followed by an overnight chase in medium without BSA-
gold. Under these conditions this marker is distributed between
the MPR-enriched prelysosomal compartments (PLCs), and the
MPR-negative lysosomes (Griffiths et al., 1988, 1990).
Morphometric analysis
Cells
Control cells were cultured in normal medium (RPMI-10% FCS)
and for leupeptin treatment the cells were incubated for 10 h in
medium with 150 µg/ml leupeptin before processing.
Mean cell volume
The methods for estimating the mean cell volume have been
described in detail previously (Griffiths et al., 1984a, 1989). The
‘volume weighted’ nuclear volume (V¯nuc) of Mel Juso cells was
estimated by using the ‘linear intercept method’, developed by
Gundersen and Jensen (1985). For this method to be accurate the
mean cell volume of all the cells in the population must be approx-
imately the same. In this paper we have assumed this to be the
case: any deviation from this assumption will be reflected in a
corresponding overestimation of the mean cell volume. The
volume fraction of nuclei (volume density, Vv uc, ce) was then esti-
mated by point counting. For this, random sections of Epon-
embedded cells (± leupeptin) were photographed at a magnifica-
tion of ´ 4,000. All measurements were made on negatives
enlarged ´ 4.1 on an EMBL-designed enlarger. A lattice grid (D64)
was placed over the projected negatives and the Vvnuc, cewas esti-
mated by relating the points over the nucleus to those over the
cell. Knowing the values for the nuclear volume and the fraction
of the cell occupied by the nucleus enabled us to estimate the
mean cell volume.
Diameter and volume of ECVs
Diameters and volumes of ECVs were determined as described
by Weibel (1979). Cryosection of Mel Juso cells (± leupeptin)
with ECVs were photographed at a magnification of ´ 16,000.
Diameters of the ECVs were determined on ´ 4.1 e larged nega-
tives. Smaller ECV profiles were not readily distinguishable from
other vesicle types, since their typical membrane-rich morphology
is not so obvious. Therefore, the measured diameters were grouped
into classes to make a histogram showing the distribution of the
ECV diameters. On the basis of the histogram, the ‘missing’
values for smaller ECVs were extrapolated (for details see Weibel,
1979). The calculation for the diameter was performed as dis-
cussed by DeHoff (1968), which enabled us to determine the mean
volume of a spherical ECV.
Number of ECVs per cell
The volume density of ECVs in the cytoplasm (Vvecv, cy) was
determined in Mel Juso cells (± leupeptin) using point counting
method (Weibel, 1979). A total of 29 micrographs were taken at
random from cryo-sections. Using a double-lattice grid (D64) the
Vvecv, cywas calculated by relating the number of points over
ECVs to the total number of points over the cytoplasm. Together
with the known values of cytoplasmic and ECV volumes, the
number of ECVs per cell could then be determined.
Quantification of immunolabelling
Cells were prepared for cryo-section and labelled with the appro-
priate antibodies followed by Protein A-gold. The number of gold
particles per linear µm of ECV peripheral membrane profile was
determined by intersection counting, and the number of gold par-
ticles per µm2 surface area of ECVs and PLCs was estimated by
point counting. The PLC was defined as profiles on sections with
at least three gold particles labelling the MPR. The quantification
of the density of gold particles was carried out as described by
Griffiths and Hoppler (1986). For background labelling the
number of gold particles over the nucleus was counted and sub-
stracted from the total number.
Results
After their transport from the Golgi complex to endocytic
compartments the newly synthesized Ii molecules are
sequentially degraded in Mel Juso cells. As shown previ-
ously, three distinct electrophoretic forms of Ii, still asso-
ciated with class II molecules, could be identified: the 33
kDa mature Ii is sequentially cleaved into P22, P18 and
fi nally P12 (Pieters et al., 1991). In the latter study it was
shown that MHC class II molecules with associated P22
accumulated when cells were pretreated with leupeptin,
pulse labelled and chased for 4 h. In order to discover
whether the MHC class II complex with the processing
intermediate P22 could be maintained for longer times we
chased the cells for up to 17 h in the presence of leupeptin.
Antigens from the cell lysates were immunoprecipitated
with an anti-MHC class II antibody (L-243), which recog-
nizes only oligomeric MHC class II molecules. As expected
Fig. 1.Effect of leupeptin on the proteolytic processing of the
MHC class II-associated invariant chain (Ii). Cells were incubated
for 4 h in medium (±) leupeptin (150 m g/ml) and then pulse
labelled for 30 min with [35S]methionine and chased (± leupeptin)
for the indicated times. Proteins were immunoprecipitated with
anti-class II antibody L-243. Shown are autoradiographs after
SDS-PAGE and fluorography. The migration of molecular mass
markers (in kDa) is indicated on the right side of the lanes. The a
and b chain of MHC class II and Ii and its proteolytically
processed forms P22, P18 and P12 are indicated on the left side. 
h
kDa
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only small amounts of MHC class II molecules could be
immunoprecipitated directly after the pulse labelling (Fig.
1). After a 2 h chase, MHC class II a (35 kDa) and b (29
kDa) chains, the associated Ii (33 kDa) and its processed
forms P22, P18 and P12 were immunoprecipitated (Pieters
et al. 1991). For chase times up to 17 h in the presence of
the protease inhibitor an accumulation of complexes of
MHC class II with associated P22 was observed.
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Fig. 2.Intracellular localization of Ii in
Mel Juso cells grown in the presence (A,
C, E, G) or absence (B, D, F, H) of
leupeptin. Cells were grown on coverslips
and incubated for 7 h (C, D), overnight
(E, F) and for 2 days in medium (±) 150
m g/ml leupeptin. Cells were fixed and
permeabilized using paraformaldehyde
and Triton X-100. Ii molecules were
labelled using the monoclonal N-terminal
antibody Vic Y1 (A, C, E, G) and the
monoclonal C-terminal antibody LN2 (B,
D, F, H). The primary antibodies were
visualized using FITC-conjugated second
antibody. Bar, 18.5 m m.
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Characterization of the effect of leupeptin on the
localization of Ii by light microscopy
Light microscopy was used to investigate the accumulation
of Ii and P22 in cells treated with leupeptin for different
times. Mel Juso cells were cultured both with and without
leupeptin for the times indicated in Fig. 2. For localizing Ii
and P22 two different antibodies were used. VIC Y1 rec-
ognizes an N-terminal, cytoplasmic determinant (anti-IiN)
while LN2 recognizes a C-terminal, luminal epitope of Ii,
which is not present in P22 (anti-IiC) (Wraight et al., 1990;
Pieters et al. 1991). The labelling patterns observed with
the two antibodies were quite different (Fig. 2). In the
absence of leupeptin both antibodies gave a strong labelling
in the perinuclear region as well as of vesicular structures
in the peripheral cytoplasm, with the latter more pro-
nounced. Following leupeptin treatment this pattern did not
significantly change with respect to the anti-IiC. Starting at
7 h and becoming more pronounced after overnight and two
days of treatment with leupeptin, there was an increased
labelling with anti-IiN (Fig. 2C, E and G). A strong
labelling for Ii was detected in distinct vesicular structures
both in the nuclear region and in the peripheral cytoplasm.
As expected, since P22 is not recognized by anti-IiC
(Pieters et al., 1991), the P22-containing vesicles which
accumulated after leupeptin treatment could not be labelled
with this antibody.
Characterization of the effect of leupeptin on the
localization of Ii by electron microscopy
The effect of leupeptin on the distribution of Ii was fol-
lowed using thawed cryosections and immunogold
labelling. Our previous study using this approach had
shown that, in addition to the Golgi complex, three distinct
endocytic organelles could be labelled with the two anti-Ii
antibodies (Pieters et al., 1991). These are the early endo-
some, the multivesicular body-like, endosome carrier vesi-
cles (ECV) and the MPR-enriched PLC. In the present study
we examine the effects of leupeptin on the distribution of
Ii with respect to these compartments.
In order to facilitate identification of the various endo-
cytic compartments BSA-gold conjugates were added to the
culture medium of the cells prior to fixation. For late endo-
cytic structures (PLC or lysosomes) 16 nm gold-BSA was
pulsed for 4 h and chased overnight. For early endosomes
5 nm gold BSA was internalized for 5 min while a 30 min
continuous internalization with this conjugate was used to
label all endosomal compartments up to the PLC. These
cells were then prepared for cryo-sectioning and labelled
with anti-IiN.
The labelling pattern seen with the anti-IiN was essen-
tially the same in both untreated and leupeptin-treated cells.
As observed in our earlier study (Pieters et al., 1991), there
was significant labelling of early endosomes, ECV (Fig. 3)
and the PLC (not shown). In both conditions the labelling
of the ECV with the anti-IiN was predominantly on the
outer membrane of these vesicles rather than on the inner,
predominantly tubular membranes (Fig. 3). The quantita-
tive data presented in Table 1 show that the concentration
of the antigen in the ECV was the same in the presence or
absence of the inhibitor. Further, in both cases an analysis
of the distribution of the gold particles indicated that
between 70 and 75% of the label was associated with the
outer membrane (within 20 nm) of the ECV.
In these cryosection preparations, a striking difference in
the leupeptin-treated cells was that there appeared to be
many more ECV when compared with untreated cells. To
investigate this further, conventional plastic embedding
studies were done. For this, cells were first incubated with
BSA-16 nm gold for 4 h, followed by a 10 h chase to label
both PLC and lysosomes (Griffiths et al., 1990). The chase
medium contained HRP to label all endocytic structures.
After incubation with DAB and embedding in Epon, the
HRP-labelled endocytic structures were visualized at low
Fig. 3.Localization of Ii in ECVs in
Mel Juso cells that were treated with
leupeptin. Cells were allowed to
internalize BSA-16 nm gold for 4 h,
followed by an overnight chase in
gold-free medium that contained
150 m g/ml leupeptin to label PLCs
and lysosomes. Before preparation
of cryosections, cells were
incubated in medium (+ leupeptin)
enriched with BSA-5 nm gold for 20
min to label early endosomes and
ECV. Sections were labelled with
anti-IiN antiserum and Protein A-9
nm gold (large arrowhead).
Colocalization of 5 nm gold (small
arrows) and Ii is found in the ECV.
Note that the labelling for Ii is
predominantly associated with the
outer membrane of ECV. Adjacent
to the ECV is a structure containing
the 16 nm gold (large arrow) that is
devoid of Ii or small gold. From its
morphological appearance and
complete lack of Ii this structure is
probably a lysosome. Bar, 100 nm.
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magnification by electron microscopy. In these preparations
the ECV are easily identified both by their morphological
features and, in this experiment, by the presence of reac-
tion product for HRP. Comparison of Fig. 4 (2 leupeptin)
and 5 (+ leupeptin) shows that leupeptin treatment does
appear to increase the number of ECVs per cell. The typi-
cal multivesicular body-like morphology of these spherical
endocytic vesicles in these plastic sections is shown in Fig.
6. In Fig. 7 three examples are shown of the structure of
the ECV in cryosections either unlabelled (7A) or follow-
ing labelling with the anti-IiN (7B) or anti-IiC (7C). The
tubular appearance of the internal membranes of the ECV
is especially evident in these images as well as apparent
continuities between the outer and inner membranes (Fig.
7A).
Quantification of the number of ECV
We next quantified the number of ECVs per cell in leu-
peptin-treated and untreated cells using a stereological
ppr ach (see Materials and methods). For this, we first
est mated the mean cell volume of both sets of cells. This
parameter provided a reference for the subsequent deter-
mination of the volume density of ECVs. As shown in Table
2, leup ptin had no significant effect on mean cell volume.
Using a point counting method the volume fraction of ECV
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Table 1.Quantification of the effect of leupeptin on Ii
labelling in ECV
Ii labelling - Leupeptin 1Leupeptin
No. gold particles per ECV 0.225 ± 0.042 0.224 ± 0.039
membrane outer profile
(gold/µm)
No. gold particles per 0.76 ± 0.29 0.84 ± 0.20
ECV area (gold/µm2)
Number of micrographs: - leupeptin, 34; + leupeptin, 18. Background:
unspecific labelling was estimated by counting the gold particles over the
nucleus (0.29 particle/µm2).
Fig. 4.Epon sections of control (untreated) Mel Juso cells that had internalized BSA-gold and HRP to identify endocytic compartments.
Cells were incubated with BSA-16 nm gold for 4 h, followed by a 10 h chase in medium containing 5 m g/ l HRP. By this procedure the
gold-marker enriches in PLCs and lysosomes and all endocytic compartments are labelled with HRP. The HRP reaction product fills a
number of vesicles close to the Golgi stack (G). ECVs can be identified by their typical morphology (arrows). Other HRP-positive
vesicles with a more irregular shape are probably early and late endosomes (arrowheads). Compartments that are HRP-positive and
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Fig. 5.Epon sections of leupeptin-treated Mel Juso cells that had internalized BSA-gold and HRP to identify endocytic compartments.
Cells were incubated for 4 h with BSA-16 nm gold and chased for 10 h in medium that contained 150 m g/ml leupeptin and 5 mg/ml HRP.
A low-magnification image of a cell is shown in (A), where the HRP-positive ECVs (arrowheads) are the predominantly reactive
structures. One prelysosomal or lysosomal structure (arrow) labelled with BSA-gold is unreactive for HRP. G, Golgi; N, nucleus; P,
plasma membrane. Bar, 0.5 m m. (B) A higher magnification image to show details of typical ECVs (single arrowheads) and other
endocytic compartments (double arrowheads) that are HRP-positive. One PLC or lysosome (arrow) containing BSA-gold is HRP-
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per cell was next estimated. There was clearly a significant
increase in this parameter following leupeptin treatment,
which led to a significant increase in their volume (Table
2). There was also a slight increase in the mean diameter
of the ECV following leupeptin treatment. Assuming that
the ECVs are spherical we can provide an estimate of the
average volume of one ECV from the average diameter.
The volume fraction of the ECV per cell multiplied by the
mean cell volume gives the total volume of these vesicles
per cell. This parameter, divided by the mean volume of
the average vesicle, gives the average number of ECVs per
cell. Leupeptin increases this number from 281 in the con-
trol to almost 550 in leupeptin-treated cells (Table 2).
Effe t of leupeptin on transport of endocytosed material
fro  ECV to PLC
The experiments described above demonstrate that leu-
peptin results in a significant increase in the number of
ECVs per cell. It was previously argued that the ECVs func-
tion to transport endocytosed material from the early endo-
some to the PLC (see Griffiths and Gruenberg, 1991). We
therefore investigated whether an increase in the number of
ECVs seen following leupeptin treatment had any effect on
the transport of an endocytic marker from the ECV to the
PLC. For this, cells were first allowed to internalize HRP
for 10 h either with or without leupeptin. PLCs and lyso-
somes were labelled with BSA-16 nm gold as described
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Fig. 6.Structure of ECVs in Epon sections. The spherical multivesicular body-like morphology is evident. Bar, 100 nm.
Fig. 7.Examples of ECV images in cryosections. (A) is unlabelled, while (B) and (C) are from cells labelled with anti-IiN and -IiC,
respectively, followed by Protein A-gold. The arrows indicate the tubular profiles within the lumen, while the arrowhead in A shows a
possible continuity between the outer membrane and an internal membrane profile. Bars, 50 nm.
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above. As shown in Figs 3 and 4, the reaction product of
the endocytic marker HRP was seen in typical endocytic
structures in both treated and untreated cells. These
included the ECVs, which, as expected, appeared more
numerous in the cells treated with leupeptin. However, the
late endocytic organelles (which include the PLC) that were
labelled with 16 nm internalized gold particles showed
much less reaction product for HRP in the leupeptin-treated
cells. This suggested that in these cells the HRP was being
transported less efficiently to the late endocytic structures.
In order to characterize this effect in more detail the fol-
lowing experiment was performed. The cells, with or with-
out leupeptin were allowed to internalize BSA-16 nm gold
followed by HRP for 10 h as described above. Cryosec-
tions were then prepared and were double-labelled with
antibodies specific for HRP and MPR. The latter serves to
identify the PLC, which was also labelled with the 16 nm
gold. The ECVs were again identified by morphological cri-
teria. The amount of HRP present in the PLC was quanti-
fi ed using anti-HRP and Protein A-gold in untreated and
leupeptin-treated cells (Fig. 8). As shown in Table 3, fol-
lowing leupeptin treatment the density of labelling for HRP
in the ECVs was not influenced by the protease inhibitor.
In untreated cells the density of labelling for HRP in the
PLC reached similar values to that seen in the ECV. How-
ever, in leupeptin-treated cells the labelling of HRP in the
PLC was reduced by 50%. Collectively, these data argue
strongly that leupeptin significantly inhibits the delivery of
the endocytic marker from the ECV to the PLC.
Discussion
Leupeptin is a protease inhibitor that mainly inhibits thiol
proteases. It has been extensively used in both in vitro and
in vivo studies to block protein degradation. When added
to the culture medium of living cells it is taken into the
endocytic pathway, presumably by fluid-phase endocytosis.
In principle, it could block thiol proteases anywhere in this
pathway. When used in this fashion it can block the degra-
dation of the MHC class II-associated invariant chain. In
previous studies this block in degradation coincided with
the accumulation of an intermediate form of the Ii, P22
(Pieters et al. 1991). The simplest interpretation of those
data was that the protease(s) responsible for the further
degradation of P22 to P18 and P12 were inhibited by leu-
peptin. In the present study an alternative interpretation
appears equally possible: that the further degradation of P22
is inhibited because of a transport block proximal to the
PLC, a compartment expected to contain relatively high
concentrations of proteases.
The immunofluorescence data show that with increasing
times after adding leupeptin to the culture medium the Mel
Juso cells showed a large increase in the number of vesi-
cles that were labelled with the anti-IiN terminus, but not
the anti-IiC terminus, antibody. This argues that these vesi-
cles are enriched in molecules of Ii which have been pro-
teolytically processed at their luminally orientated C ter-
minus. As seen by electron microscopy these vesicles
correspond to the multivesicular body-like ECV. In a pre-
vious study these structures could be labelled with anti-
bodies against both the N and C terminus of Ii (Pieters et
al., 1991). The accumulation of these vesicles following
leupeptin treatment coincided with the accumulation of P22.
This suggests that under normal conditions the proteolytic
step from the mature Ii to this P22 form either occurs pre-
dominantly in the ECV, or at least begins in these struc-
tures (or earlier) and continues in the PLC. The finding that
the PLC can be significantly labelled with both anti-IiN and
anti-IiC antibodies in the absence of leupeptin (Pieters et
al., 1991) argues more for the latter possibility.
From a previous study on the endocytic pathway it has
been proposed that the ECV bud off the early endosome
and are transported in a microtubule-dependent fashion to
the perinuclear region of the cell where they fuse with the
PLC (see Griffiths and Gruenberg, 1991, for review). The
results of the present study are entirely consistent with this
view. The doubling in the number of ECVs by leupeptin
coincided with a significant decrease in the delivery of HRP
into the PLC. This effect of leupeptin is consistent with the
data of Tolleshaug and Berg (1981), who showed that pre-
tre tment of rat hepatocytes with leupeptin blocked the
degra ation of internalized asialofetuin, an effect that cor-
related with an inhibition in transport from low density vesi-
cles to high density lysosomes.
The simplest interpretation of our data is that leupeptin
does not affect the formation of the ECV, but rather some
step leading to their fusion with the PLC. It is an intrigu-
ing qu stion as to how the presence of a protease inhibitor
on the luminal side of a compartment (at least predomi-
nantly) could affect an event that occurs on the cytoplas-
mic face of its membrane. One possibility is that the accu-
Table 2. Stereological ECV estimation of the number of
ECVs per cell
- Leupeptin + Leupeptin
Nuclear volume (m m3)* 421.46 ± 62.77 507.10 ± 76.10
Volume density, nuclei per cell39.67 ± 5.26 42.03 ± 7.38
(% of total cell volume)†
Cell volume (m m3) 1062.41 ± 158.91206.52 ± 181.10
Cytoplasm volume (m m3) 640.70 ± 95.40 698.99 ± 104.76
ECV diameter (m m) 0.258 ± 0.038 0.350 ± 0.044
Average volume of one ECV (m m3) 0.009 ± 0.001 0.0224 ± 0.0028
Volume density ECV‡ 0.394 ± 0.072 1.759 ± 0.192
(% of cell volume)
Total volume ECV/cell (m m3) 2.53 ± 0.357 12.29 ± 1.84 
Total number ECV/cell 281.11± 41.69 548.66± 82.35
*Number of nuclear profiles, 275.
†Number of micrographs, 20.
‡Number of micrographs, 30.
Table 3.Quantification of the effect of leupeptin on
endocytosed HRP in ECVs and PLCs
HRP labelling - Leupeptin + Leupeptin
(gold/µm2) (n= 30) (n= 25)
Gold per area ECV 99.45 ± 10.90 94.88 ± 10.74
Gold per area PLC 84.85 ± 17.52 41.56 ± 10.75
Background: unspecific labelling was estimated by counting the gold
particles (6 and 9 nm) over the nucleus (0.33 particles/µm2). The ECVs
were defined on morphological criteria; that is, spherical, multivesicular-
body-like vesicles; while the PLC was defined as profiles containing at
least 3 gold particles labelling the MPR. n, number of micrographs.
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Fig. 8.Examples of images from the triple-labelling of Mel Juso cells, used to quantify the amount of HRP that is transported from ECVs
to PLCs. Cells were allowed to internalize BSA-16 nm gold for 4 h, followed by a 10 h chase to label PLC (large arrows) and lysosomes
(L). The chase medium contained HRP to label all endocytic structures. (A) Shows the control cell, while (B) indicates the leupeptin-
treated cells. Cryosections were prepared and double-labelled with anti-HRP and 9 nm gold (small arrowheads) and anti-MPR and 5 nm
gold (small arrows). (A) Shows two vesicular profiles (large arrows) that contain internalized BSA-gold, are also positive for HRP and
MPR, and which we classify as PLC. Two ECVs (large arrowhead) that are HRP-positive are located close to a Golgi-stack (G). One of
these ECVs contains two gold particles for MPR. P, plasma membrane. In (B) an ECV (large arrowhead) is labelled with HRP but not
with MPR and is seen adjacent to a profile of a lysosome (L) that is characteristically amorphous, MPR-negative and contains the
internalized BSA-gold. In this example no HRP is seen. On the right a typical PLC profile is seen (large arrow) that is significantly
labelled with both HRP and MPR. It also contains the 16 nm internalized gold (unmarked). Bar, 0.2 m . 
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mulation of undegraded molecules in the PLC leads to
release of a factor(s) into the cytosol, which blocks the bind-
ing or fusion of the ECV with the PLC. This would be an
example of feedback inhibition which could serve to regu-
late the entry of material from the endocytic pathway into
the PLC. That this step is somehow regulated is suggested
by our observations that the number of ECVs appears to
vary greatly between different cell types. Thus, while Mel
Juso cells have relatively high numbers, even without leu-
peptin, these structures are very difficult to find in MDCK
cells unless their transport is blocked with the microtubule-
depolymerizing drug nocodazole (Parton et al., 1989;
Bomsel et al., 1990). In a recent study it was also found
that the ECV to PLC step was blocked in macrophages that
had been allowed to accumulate wheat germ agglutinin
(Rabinowitz et al., 1992); in the latter study the lectin
responsible for the block was only present on the luminal
side of the endocytic organelles. An alternative possibility
to explain how leupeptin could inhibit fusion of ECVs with
the PLCs is that this process is dependent on a fusion-active
transmembrane protein. This protein might be activated on
its cytosolic side by being degraded from its luminal side.
In leupeptin-treated cells the protease that normally gener-
ates the fusion-active protein could be inhibited and the
ECVs would accumulate. Further studies are needed to
determine the actual mechanism of inhibition.
In this paper we use the term ECV for an endocytic com-
partment that is reached by the endocytosed marker HRP
after having passed early endosomes and before reaching
late endosomal structures. The ECVs are often referred to
as multivesicular bodies because of the vesicular profiles
that fill their lumen. This term usually assumes that vesic-
ular profiles represent free vesicles that have budded into
the lumen and that membrane proteins destined for degra-
dation are sorted into these vesicles (Hopkins, 1986; Felder
et al., 1990; Hopkins et al., 1990; Warren, 1990). Our data
in this and in earlier studies are inconsistent with this view.
In the cell types we have studied, using thawed cryosec-
tions, most of the internal membranes are tubular rather
than vesicular; at least some of the tubules are accessible
to externally added markers in preparations in vitro (R.
Parton and J. Gruenberg, unpublished data). Further, in
some cell types we could detect two recycling receptors,
transferrin receptor and MPR, on the internal membranes
of these vesicles (Killisch et al., 1992). In contrast, as
shown in this, as well as in our previous study (Pieters et
al., 1992), the Ii, a molecule predominantly destined for
degradation, is preferrentially associated with the outer
membrane of the ECV. While the mechanism of biogene-
sis of the ECV is still unknown, these observations con-
tradict the MVB model in its present form.
Finally, our data have implications for antigen presenta-
tion, especially with regard to the intracellular transport of
the MHC class II-Ii complex. As P22 accumulates in leu-
peptin-treated cells in ECVs, further proteolytic degrada-
tion of P22 might be obligatory for dissociation of the Ii
from the MHC class II molecules and for the expression of
MHC class II molecules on the cell surface (Neefjes and
Ploegh, 1992). If some of these proteolytic events normally
occur in the ECV, these organelles might be one of the sites
where foreign antigens are proteolytically processed and
bind MHC class II molecules. In fact, it has been shown
t at leupeptin does inhibit the presentation of some soluble
proteins (Takahashi et al., 1989; Streicher et al., 1984).
These observations were explained by assuming that leu-
pepti  inhibits antigen processing. Our data show that the
leupeptin effect is more complex. This drug not only
inhibits proteolysis in the endocytic pathway but also
reduc s the transport rate from the cell surface to prelyso-
somal compartments.
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